Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review
- PMID: 40002394
- PMCID: PMC11851550
- DOI: 10.3390/antiox14020208
Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review
Abstract
Peyronie's disease (PD) is a chronic disease characterized by the development of fibrous tissue in the tunica albuginea of the penile corpora cavernosa that causes penile deformity. The precise cause of PD is not completely understood, but it is generally believed to be initiated by a specific injury in the affected area. Research has consistently shown that oxidative stress (OS) is a key player in PD. Pentoxifylline (PTX) is a synthetic derivative of methylxanthine that was initially used for the management of peripheral vascular disease. PTX has also been used in humans for several inflammatory and fibrotic conditions, including PD. PTX has several mechanisms of action, including antioxidant, antifibrotic, anti-inflammatory, and vasorelaxant. This article aims to verify, after a review of the literature regarding the use of PTX in PD, whether this substance is really able to cure PD. We conducted research by consulting the scientific literature on the topic. Results: After examining 39 articles, we considered 20 articles eligible for our narrative review, including a single randomized controlled clinical study, six clinical studies with a control group, a single uncontrolled clinical study, eight case report studies, and four systematic review articles. Conclusions: Although the systematic review articles selected in this paper showed no consistent evidence regarding the efficacy of PTX, in our opinion, the clinical studies we have analyzed undoubtedly demonstrate that PTX is able to combat PD, thanks to its ability to interfere with the pathogenic mechanisms of the disease. However, we believe that further new randomized controlled trials are necessary to more clearly demonstrate the effectiveness of PTX in the treatment of PD.
Keywords: Peyronie’s disease; antioxidants; oxidative stress; pentoxifylline.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.Res Rep Urol. 2017 Jul 20;9:129-139. doi: 10.2147/RRU.S141748. eCollection 2017. Res Rep Urol. 2017. PMID: 28791261 Free PMC article.
-
Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants.Int J Mol Sci. 2022 Dec 15;23(24):15969. doi: 10.3390/ijms232415969. Int J Mol Sci. 2022. PMID: 36555611 Free PMC article. Review.
-
Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.J Med Case Rep. 2022 Oct 8;16(1):359. doi: 10.1186/s13256-022-03614-1. J Med Case Rep. 2022. PMID: 36207748 Free PMC article.
-
Efficacy of pentoxifylline in Peyronie's disease: Clinical case of a young man.Arch Ital Urol Androl. 2014 Sep 30;86(3):237-8. doi: 10.4081/aiua.2014.3.237. Arch Ital Urol Androl. 2014. PMID: 25308598
-
Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.Inflamm Allergy Drug Targets. 2012 Feb;11(1):48-57. doi: 10.2174/187152812798889321. Inflamm Allergy Drug Targets. 2012. PMID: 22309083 Review.
References
Publication types
LinkOut - more resources
Full Text Sources